Abnormal metabolic network activity in REM sleep behavior disorder

Neurology

Volumn 82, Issue 7, 2014, Pages 620-627

  Holtbernd, Florian ^a   Gagnon, Jean François ^b,c   Postuma, Ron B ^b,d   Ma, Yilong ^a   Tang, Chris C ^a   Feigin, Andrew ^a   Dhawan, Vijay ^a   Vendette, Mélanie ^b,c   Soucy, Jean Paul ^e   Eidelberg, David ^a   Montplaisir, Jacques ^b,f  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^c UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^d MONTREAL GENERAL HOSPITAL   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DIMER; ETHYLCYSTEINATE DIMER; FLUORODEOXYGLUCOSE F 18; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN SCINTISCANNING; CAMERA; CEREBELLUM; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; FOLLOW UP; GLOBUS PALLIDUS; HUMAN; IDIOPATHIC DISEASE; LEFT HEMISPHERE; MIDDLE AGED; NERVOUS SYSTEM PARAMETERS; NEUROIMAGING; NEUROLOGIC DISEASE; PARASOMNIA; PARKINSON DISEASE; PARKINSON DISEASE RELATED COVARIANCE PATTERN; PARKINSONISM; PET SCANNER; PHENOCONVERSION; PHENOTYPE; PONS; POSITRON EMISSION TOMOGRAPHY; PRIMARY MOTOR CORTEX; PRIORITY JOURNAL; PUTAMEN; RIGHT HEMISPHERE; RISK FACTOR; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBTHALAMUS;

AGED; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; LEWY BODY DISEASE; MIDDLE AGED; MULTIMODAL IMAGING; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; REM SLEEP BEHAVIOR DISORDER; SINGLE-BLIND METHOD; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84895745657     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000130     Document Type: Article

References (33)

1. Iranzo A, Molinuevo JL, Santamaria J, et al. Rapid-eyemovement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol 2006;5:572-577.
2. Postuma RB, Gagnon JF, Montplaisir JY. REM sleep behavior disorder: from dreams to neurodegeneration. Neurobiol Dis 2012;46:553-558.
3. Boeve BF. REM sleep behavior disorder: updated review of the core features, the REM sleep behavior disorderneurodegenerative disease association, evolving concepts, controversies, and future directions. Ann NY Acad Sci 2010;1184:15-54.
4. Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target largescale human brain networks. Neuron 2009;62:42-52.
5. Eidelberg D. Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. Trends Neurosci 2009;32:548-557.
6. Niethammer M, Eidelberg D. Metabolic brain networks in translational neurology: concepts and applications. Ann Neurol 2012;72:635-647.
7. Tang C, Poston K, Eckert T, et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol 2010;9:149-158.
8. Ma Y, Tang C, Spetsieris P, Dhawan V, Eidelberg D. Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility. J Cereb Blood Flow Metab 2007;27:597-605.
9. Spetsieris PG, Eidelberg D. Scaled subprofile modeling of resting state imaging data in Parkinson's disease: methodological issues. Neuroimage 2011;54:2899-2914.
10. Huang C, Tang C, Feigin A, et al. Changes in network activity with the progression of Parkinson's disease. Brain 2007;130:1834-1846.
11. Tang C, Poston K, Dhawan V, Eidelberg D. Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease. J Neurosci 2010;30:1049-1056.
12. Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 2009;72:1296-1300.
13. Dang-Vu TT, Gagnon JF, Vendette M, Soucy JP, Postuma RB, Montplaisir J. Hippocampal perfusion predicts impending neurodegeneration in REM sleep behavior disorder. Neurology 2012;79:2302-2306.
14. Vendette M, Gagnon JF, Soucy JP, et al. Brain perfusion and markers of neurodegeneration in rapid eye movement sleep behavior disorder. Mov Disord 2011;26:1717-1724.
15. Hughes A, Daniel S, Kilford L, Lees A. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
16. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863-1872.
17. Gilman S, Wenning G, Low P, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008;71:670-676.
18. Spetsieris P, Ma Y, Peng S, et al. Identification of diseaserelated spatial covariance patterns using neuroimaging data. J Vis Exp 2013;76:e50319.
19. Eckert T, Van Laere K, Tang C, et al. Quantification of Parkinson's disease-related network expression with ECD SPECT. Eur J Nucl Med Mol Imaging 2007;34:496-501.
20. Feigin A, Antonini A, Fukuda M, et al. Tc-99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism. Mov Disord 2002;17:1265-1270.
21. Burnham KP, Anderson DR. Model Selection and Multimodel Inference. New York: Springer Verlag; 2002.
22. Eisensehr I, Linke R, Noachtar S, Schwarz J, Gildehaus FJ, Tatsch K. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder: comparison with Parkinson's disease and controls. Brain 2000; 123(pt 6):1155-1160.
23. Iranzo A, Valldeoriola F, Lomena F, et al. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol 2011;10:797-805.
24. Eckert T, Tang C, Eidelberg D. Assessment of the progression of Parkinson's disease: a metabolic network approach. Lancet Neurol 2007;6:926-932.
25. Eidelberg D, Moeller JR, Ishikawa T, et al. Early differential diagnosis of Parkinson's disease with 18F-fluorodeoxyglucose and positron emission tomography. Neurology 1995;45: 1995-2004.
26. Kagi G, Bhatia KP, Tolosa E. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry 2010;81:5-12.
27. Hirano S, Asanuma K, Ma Y, et al. Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease. J Neurosci 2008;28: 4201-4209.
28. Boeve BF, Silber MH, Saper CB, et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain 2007;130:2770-2788.
29. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
30. Klein JC, Eggers C, Kalbe E, et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 2010;74:885-892.
31. Jellinger KA. A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathol 2008;116:1-16.
32. Poston K, Tang C, Eckert T, et al. Network correlates of disease severity in multiple system atrophy. Neurology 2012;78:1237-1244.
33. Ben-Shlomo Y,Wenning GK, Tison F, Quinn NP. Survival of patients with pathologically proven multiple system atrophy: a meta-analysis. Neurology 1997;48:384-393.